The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Clinical actionability of molecular targets in endometrial cancer
Open accessAbstract
Endometrial cancer accounts for ~76,000 deaths among women each year worldwide. Disease mortality and the increasing number of new diagnoses make endometrial cancer an important consideration in women's health, particularly in industrialized countries, where the incidence of this tumour type is highest. Most endometrial cancers are carcinomas, with the remainder being sarcomas. Endometrial carcinomas can be classified into several histological subtypes, including endometrioid, serous and clear cell carcinomas. Histological subtyping is currently used routinely to guide prognosis and treatment decisions for endometrial cancer patients, while ongoing studies are evaluating the potential clinical utility of molecular subtyping. In this Review, we summarize the overarching molecular features of endometrial cancers and highlight recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the combined presence of PTEN and PIK3CA or PIK3R1 mutations are frequently observed suggesting that both loss of tumor suppressor and activation of oncogenes is required during tumor progression53.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Talhouk, A., McConechy, M. K., Leung, S. C. Y., Yang, W., Lum, A. M., Senz, J., Boyd, N., Pike, J. A., Anglesio, M. S., Kwon, J. S., et al. (2017) · Cancer · doi:10.1002/cncr.30496 · Cited by 1,007
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S. C. Y., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 989
Stelloo, E., Nout, R. A., Osse, E. M., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Nijman, H. W., Putter, H., Bosse, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2878 · Cited by 856
Cited by
Sorted by citations
Items 401–411 of 411
Dietary and circulating fatty acids in association with ovarian and endometrial cancers
Ghantous, S. Y. (2020) · theses.fr (ABES) · doi:10.70675/d85ab521zecfdz4941zbcecz6cd11d811649
Endogenous mutational mechanisms and metabolic context shape endometrial cancerPreprint
Sang, J., Zhang, M., Chavez, S., Kim, Y. M., Veith, T. A., Zhou, W., Luo, W., Miranda, A. M., Luebeck, J., Wang, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.03.716356
Zhu, Z., Yuan, J., Liu, N., Gao, Y., Fu, X., & Yan, L. (2026) · Discover Oncology · doi:10.1007/s12672-026-05026-9
Fluoxetine Modulates Apoptosis and ERK1/2 Phosphorylation in Endometrial Cancer In VitroPreprint
Arı, N. S., Gündoğdu, A. Ç., Meriç, N., & Özatik, O. (2026) · Research Square · doi:10.21203/rs.3.rs-8850312/v1
Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case–Control Study
Bağlar, İ., Şanlıkan, F., Keleş, E., Kara, S. S., Ergenç, C., Dönmez, Y. Ç., & Uzun, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093409
MOSAIC: Model-based, Subgroup-Aware Identification of Driver Mutations in CancerPreprint
Campbell, K. S., & Reyna, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721672
From Biopsy to Biology: Next-Generation Sequencing in Endometrial, Ovarian, and Cervical Carcinoma
Vellone, V. G., Gaggero, G., & Paudice, M. (2026) · Current clinical pathology · doi:10.1007/978-3-032-18790-1_9
Sun, Y., Wang, X., Wu, F., Ji, Y. P., & Xie, J. (2026) · Biology · doi:10.3390/biology15130987
Fan, C., Zhang, X., Li, M., Wang, W., Li, Z., Lu, Q., Teng, F., & Ge, L. (2026) · AJOG Global Reports · doi:10.1016/j.xagr.2026.100670
Zhong, S., Liu, J., Xu, H., Lv, J., Li, H., Hu, H., Xiao, S., Xie, X., Li, Y., Wu, Y., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08606-z
Arı, N. S., Gündoğdu, A. Ç., Meriç, N., & Özatik, O. (2026) · Life · doi:10.3390/life16101629
Metadata
- Authors
- Urick, M. E., & Bell, D. W.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Bell, Daphne W.
- Venue
- Nature Reviews Cancer
- Published
- 2019-08-06
- Volume
- 19
- Issue
- 9
- Pages
- 510-521
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC7446243
- OpenAlex
- W2965204233
- Cited by
- 405
- References
- 157
- Citations by year
- 2026: 19 · 2025: 57 · 2024: 58 · 2023: 70 · 2022: 101 · 2021: 66 · 2020: 32 · 2019: 2
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 HG999999)
- National Human Genome Research Institute (Z01HG200338, ZIAHG200379, ZIAHG200338)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- endometrial cancer, molecular subtyping, molecular targets, targeted therapy, early detection, risk stratification, endometrioid carcinoma, serous carcinoma, clear cell carcinoma, histological subtypes, prognosis
- MeSH terms
- Animals, Carcinoma, Female, Humans, Immunotherapy, Mutation, Prognosis, Risk, Sarcoma, Biomarkers, Tumor, Endometrial Neoplasms, Risk Assessment, Proteomics, Mice, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
